AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2017
Aug 17, 2017
32870_dirs_2017-08-17_28409139-dc1e-467b-be2e-bb1d145c1256.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-08-15
Reporting Person: Hauer Jerome M (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-15 | Common Stock | A | 5153 | $25.47 | Acquired | 29421 | Direct |
| 2017-08-15 | Common Stock | S | 10776 | $35.8342 | Disposed | 18645 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-15 | Stock Option (Right to Buy) | $25.47 | M | 5153 | Disposed | 2022-01-21 | Common Stock (5153) | Direct |
Footnotes
F1: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.70 to $36.05, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.